1. Scrip
  2. >>Leadership

Merck’s Perlmutter Is Retiring, Handing Over Keytruda To Li

New R&D Head Comes From Discovery And Translation Group

 
• By Mandy Jackson

Merck Research Laboratories president Roger Perlmutter returned to the company when its R&D was at a crossroads. Now he is retiring and handing the company’s post-Keytruda growth over to SVP Dean Li.  

a hand with an antique skeleton key toned with a retro vintage filter instagram app or action effect
Perlmutter will pass the Merck Research Laboratories keys to Li on 1 January • Source: Shutterstock

Merck & Co., Inc. is in better shape now than it was in 2013 when Roger Perlmutter rejoined the big pharma as president of Merck Research Laboratories, largely because of the mega-blockbuster Keytruda. Now, the company announced on 2 October, Perlmutter is retiring and handing over ongoing research and development of the PD-1 inhibitor as well as the R&D group’s efforts to generate novel products to Dean Li, senior vice president of discovery sciences and translational medicines.

Perlmutter will officially hand over the MRL keys to Li on 1 January but will remain as executive director of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

Executives On The Move: Legend Biotech Gets New CFO From AstraZeneca

Recent moves in the industry include an ex-Pfizer exec as the new CEO at Cha Vaccine Institute and a C-suite shuffle at Paragon Therapeutics, plus six other companies get new CFOs.

Quotables: Pharma Leaders On The Month’s Hot Topics

 
• By Anabel Costa-Ferreira

The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.

A Decade Of Transformation: Dong-A ST Readies For Take Off As An Innovative Pharma

 
• By Jung Won Shin

Korean firm’s head of research talks to Scrip about how it is transforming into an innovative drug developer with a more diverse pipeline across multiple modalities with first-in-class potential.

Executives On The Move: Four New CEOs Among This Week’s Changes

Recent moves in the industry include new CEO hires at Artios Pharma, Rezo Therapeutics and Gubra, plus leadership changes at X4 Pharmaceuticals.

More from Scrip

Executives On The Move: Legend Biotech Gets New CFO From AstraZeneca

Recent moves in the industry include an ex-Pfizer exec as the new CEO at Cha Vaccine Institute and a C-suite shuffle at Paragon Therapeutics, plus six other companies get new CFOs.

DualityBio Eyes 1L Use For ADC Combos With BioNTech’s Bispecific

 
• By Dexter Jie Yan

Duality is fast-tracking the development of three of its ADC candidates in combination with partner BioNTech's BNT327, an anti-PD-L1/VEGF-A bispecific antibody, in four studies, with certain cohorts evaluating first-line use in various cancers.

Lilly’s Verzenio Scores First OS Improvement In Key Breast Cancer Setting In Decades

 
• By Alaric DeArment

The drugmaker announced topline results for the CDK4/6 inhibitor in early HR-positive, HER2-negative breast cancer, giving it a competitive edge over Novartis’s Kisqali.